Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
Launched by BEIJING DITAN HOSPITAL · Oct 6, 2016
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Confirmed of stage HBV-HCCⅡb、Ⅲa、Ⅲb;
- • 2. Ages Eligible for Study: ≤75 years old;
- • 3. TCM syndrome is deficiency of both Qi and Yin;
- • 4. Confirmed of CHB;
- • 5. Surgery cannot be allowed;
- • 6. Informed consent from the patient.
- Exclusion Criteria:
- • 1. Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;
- • 2. Serious problem of heart, lung, or kidney with severe dysfunction;
- • 3. Pregnant or child breast feeding women;
- • 4. Mental or cognitive disorders;
- • 5. Participating in other drug trials;
- • 6. Who are allergic to the study drug.
About Beijing Ditan Hospital
Beijing Ditan Hospital is a leading healthcare institution in China, renowned for its expertise in neurology and neurosurgery. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a commitment to ethical standards and patient safety, Beijing Ditan Hospital collaborates with multidisciplinary teams to explore new therapies and interventions, contributing to the global body of knowledge in the medical field. Its state-of-the-art facilities and experienced researchers position the hospital at the forefront of clinical research, fostering breakthroughs that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Zhiyun Yang, PhD
Principal Investigator
Beijing Ditan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials